Agilent to Acquire GenDx for $217 Million
Ticker: A · Form: 8-K · Filed: Sep 5, 2024 · CIK: 1090872
| Field | Detail |
|---|---|
| Company | Agilent Technologies, Inc. (A) |
| Form Type | 8-K |
| Filed Date | Sep 5, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.01, $600 million |
| Sentiment | bullish |
Sentiment: bullish
Topics: acquisition, diagnostics, healthcare
Related Tickers: A
TL;DR
Agilent buying GenDx for $217M to boost diagnostics biz.
AI Summary
Agilent Technologies, Inc. announced on September 4, 2024, that it has entered into a definitive agreement to acquire all outstanding shares of GenDx for approximately $217 million. GenDx is a Dutch company specializing in molecular diagnostic solutions for transplantation and infectious diseases. The acquisition is expected to close in the fourth quarter of Agilent's fiscal year 2024.
Why It Matters
This acquisition expands Agilent's presence in the growing field of molecular diagnostics, particularly in transplantation, which could lead to increased revenue and market share in this specialized area.
Risk Assessment
Risk Level: medium — The acquisition is subject to customary closing conditions and regulatory approvals, which introduces some uncertainty regarding the completion and timing of the deal.
Key Numbers
- $217 million — Acquisition Price (Total cost to acquire GenDx)
Key Players & Entities
- Agilent Technologies, Inc. (company) — Acquiring company
- GenDx (company) — Target company
- $217 million (dollar_amount) — Acquisition price
- September 4, 2024 (date) — Date of agreement
- fourth quarter of fiscal year 2024 (date) — Expected closing period
FAQ
What is the primary business of GenDx?
GenDx specializes in molecular diagnostic solutions for transplantation and infectious diseases.
When is the acquisition expected to close?
The acquisition is expected to close in the fourth quarter of Agilent's fiscal year 2024.
What is the total value of the transaction?
The definitive agreement is for approximately $217 million.
What is Agilent Technologies' ticker symbol?
Agilent Technologies, Inc. is listed under the ticker symbol A.
What is the strategic rationale for this acquisition?
The acquisition is expected to expand Agilent's presence in the growing field of molecular diagnostics, particularly in transplantation.
Filing Stats: 877 words · 4 min read · ~3 pages · Grade level 9.9 · Accepted 2024-09-05 17:28:00
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 Par Value A New York Stock Exchange
- $600 million — d to issue and sell to the Underwriters $600 million in aggregate principal amount of its 4.
Filing Documents
- d891217d8k.htm (8-K) — 28KB
- d891217dex11.htm (EX-1.1) — 167KB
- d891217dex51.htm (EX-5.1) — 16KB
- 0001193125-24-214337.txt ( ) — 375KB
- a-20240904.xsd (EX-101.SCH) — 2KB
- a-20240904_lab.xml (EX-101.LAB) — 17KB
- a-20240904_pre.xml (EX-101.PRE) — 11KB
- d891217d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 1.1 Underwriting Agreement, dated September 4, 2024, by and among the Company, BofA Securities, Inc., J.P. Morgan Securities LLC, Mizuho Securities USA LLC and Wells Fargo Securities, LLC, as representatives of the several Underwriters. 5.1 Opinion of Goodwin Procter LLP. 23.1 Consent of Goodwin Procter LLP (included in Exhibit 5.1). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AGILENT TECHNOLOGIES, INC. By: /s/ P. Diana Chiu Name: P. Diana Chiu Title: Vice President, Assistant General Counsel and Assistant Secretary Date: September 5, 2024